Literature DB >> 24978430

Polypoidal choroidal vasculopathy in white patients.

Stephen J Davis1, Andreas K Lauer, Christina J Flaxel.   

Abstract

PURPOSE: To report on a series of white patients in the United States with polypoidal choroidal vasculopathy (PCV).
METHODS: This is a retrospective chart review of 27 patients at a single center with PCV.
RESULTS: The mean age was 74.3 with 48% being male. The most common presenting diagnosis was exudative age-related macular degeneration in 59%, and it took 17.5 months to diagnose PCV. During this time, patients received one antivascular endothelial growth factor injection every 1.3 months. The most common reason for suspecting PCV was a large retinal pigment epithelial detachment or a poor response to antivascular endothelial growth factor therapy. Once PCV was diagnosed, most underwent photodynamic therapy. In those who received photodynamic therapy, the fluid and/or age-related macular degeneration decreased in 86%. The vision improved in 41% with 36% maintaining stable vision. Patients received only one additional injection every 3.95 months after photodynamic therapy.
CONCLUSION: This is one of the larger series of PCV in an entirely white population. It emphasizes the importance of diagnosis in whites as PCV can masquerade as recalcitrant exudative age-related macular degeneration. Common findings were a temporal or peripapillary location and the presence of lipid. After photodynamic therapy, the patients still required antivascular endothelial growth factor therapy, but the injection burden was decreased by 67% and vision was found to be improved or maintained in 77% of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978430     DOI: 10.1097/IAE.0000000000000206

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  16 in total

1.  [Forms of age-related macular degeneration].

Authors:  M Schargus
Journal:  Ophthalmologe       Date:  2015-04       Impact factor: 1.059

2.  Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.

Authors:  Siyin Liu; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-09       Impact factor: 3.535

3.  Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome.

Authors:  Young Suk Chang; Jae Hui Kim; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Sung Won Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-19       Impact factor: 3.117

4.  Radiating hemorrhage in exudative age-related macular degeneration.

Authors:  Jae Hui Kim; Young Suk Chang; Jong Woo Kim; Tae Gon Lee; Chul Gu Kim; Dong Won Lee
Journal:  Jpn J Ophthalmol       Date:  2016-07-25       Impact factor: 2.447

Review 5.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

6.  Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.

Authors:  Eleftherios I Agorogiannis; Ian A Pearce; Sohraab Yadav; David G Parry; Nicholas A V Beare
Journal:  Eye (Lond)       Date:  2018-07-12       Impact factor: 3.775

7.  Analysis of the Serum Lipid Profile in Polypoidal Choroidal Vasculopathy.

Authors:  Miaoling Li; Xiongze Zhang; Nanying Liao; Baikang Ye; Yuting Peng; Yuying Ji; Feng Wen
Journal:  Sci Rep       Date:  2016-12-02       Impact factor: 4.379

8.  Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom.

Authors:  Tarek Alasil; Nelida Munoz; Pearse A Keane; Adnan Tufail; Patrick A Coady; Eduardo Novais; Talisa E de Carlo; Caroline R Baumal; Nadia K Waheed; Jay S Duker; Ron A Adelman
Journal:  Int J Retina Vitreous       Date:  2017-04-17

9.  Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.

Authors:  Gregg T Kokame; James C Lai; Raymond Wee; Ryan Yanagihara; Jessica G Shantha; Julia Ayabe; Kelsi Hirai
Journal:  BMC Ophthalmol       Date:  2016-07-27       Impact factor: 2.209

Review 10.  Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

Authors:  Alfredo García-Layana; Marta S Figueroa; Javier Araiz; José M Ruiz-Moreno; Francisco Gómez-Ulla; Luis Arias-Barquet; Nicholas Reiter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.